Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022
December 14, 2022 at 03:02 am IST
Share
Champions Oncology, Inc. reported earnings results for the second quarter and six months ended October 31, 2022. For the second quarter, the company reported net loss was USD 0.016 million compared to net income of USD 0.277 million a year ago.
For the six months, net loss was USD 0.335 million compared to net income of USD 0.105 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to basic earnings per share from continuing operations of USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to diluted earnings per share from continuing operations of USD 0.01 a year ago.
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
CHAMPIONS ONCOLOGY, INC. 
